Targets › F9
14 programs from 12 companies in 28 trials: 13 Phase 3, 6 Phase 1, 5 Phase 4, 4 Phase 2; Hematology, Cardiovascular, Neurology; next expected readout Nov 2026.
Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa. (UniProt, P00740)
Open in Phaseline: the race on F9, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Emicizumab Coagulation factor IX and X other | F9, F10 | Phase 4 | Severe Hemophilia A; Von Willebrand Disease, Type 3; Factor VIII Deficiency, Congenital; Hemophilia A Patient … | Nov 2026 |
| CSL Behring | Prothrombin Complex Concentrate (BE1116) Coagulation factor VII exogenous protein; Vitamin K-dependent protein S exogenous protein; Vitamin K-dependent protein C exogenous protein | F7, PROS1, PROC, F9, F2 | Phase 3 | Complex Cardiovascular Surgery With Cardiopulmonary Bypass; Cardiac Valve Disease; Hemophilia; Liver Cirrhosis | Apr 2027 |
| Biocad | ANB-002 (arvenacogene sanparvovec) Adeno-associated viral vector carrying the FIX gene | F9 | Phase 3 | Hemophilia B | Apr 2027 |
| IntraBio | Trenonacog Alfa (IB1001) Coagulation factor IX exogenous protein | F9 | Phase 3 | Ataxia-Telangiectasia; CACNA1A; Niemann-Pick Disease, Type C | Dec 2027 |
| Pfizer | Fidanacogene Elaparvovec (PF-06838435) Coagulation factor IX exogenous gene | F9 | Phase 3 | Hemophilia B; Hemophilia A | Feb 2028 |
| CSL Behring | Etranacogene Dezaparvovec (CSL222) Coagulation factor IX exogenous protein | F9 | Phase 3 | Hemophilia B | Oct 2028 |
| BioMarin Pharmaceutical | valoctocogene roxaparvovec Coagulation factor IX exogenous protein | F9 | Phase 3 | Hemophilia A | Mar 2029 |
| Icahn School of Medicine at Mount Sinai | Oral Anticoagulant (OAC) - Vitamin K Antagonist (VKA) or Direct Oral Anticoagula Vitamin K antagonist or factor Xa/IIa inhibitor anticoagulation | F2, F7, F9, F10 | Phase 3 | Atrial Fibrillation | – |
| Shanghai Xinzhi BioMed | BBM-H901 Adeno-associated virus (AAV) vector containing human factor IX (hFIX) transgene for gene t | F9 | Phase 2 | Hemophilia B | Jun 2028 |
| Northwell Health | FEIBA Factor VIII inhibitor bypass activity - prothrombin complex concentrate containing factors | F2, F7, F9, F10 | Phase 2 | Cardiac Disease | Nov 2028 |
| Institute of Hematology & Blood Diseases Hospital, China | ZS801 AAV vector-mediated human factor IX variant gene transfer | F9 | Phase 1 | Hemophilia B | Dec 2028 |
| Baxalta now part of Shire | AskBio009 (BAX 335) Adeno-associated virus serotype 8 (AAV8) delivering Factor IX (FIX) gene therapy | F9 | Phase 1 | Hemophilia B | Jan 2030 |
| Regeneron Pharmaceuticals | REGV131-LNP1265 Coagulation Factor IX gene insertion therapy delivered via LNP | F9 | Phase 1 | Hemophilia B | Aug 2034 |
| Institute of Hematology & Blood Diseases Hospital, China | BBM-H901 AAV5 vector encoding hyperactive human factor IX mutant (FIX Padua) | F9 | Phase 1 | Hemophilia B | Jun 2035 |
Hemophilia B (10) Hemophilia A (2) Severe Hemophilia A (2) Von Willebrand Disease, Type 3 (2) Factor VIII Deficiency, Congenital (1) Hemophilia A Patient (1) Acquired Hemophilia A (1) Ataxia-Telangiectasia (1) CACNA1A (1) Niemann-Pick Disease, Type C (1) Cardiac Disease (1) Atrial Fibrillation (1)
other (6), small molecule (5), protein or peptide (2), mixed (1)
CSL Behring (2) Institute of Hematology & Blood Diseases Hospital, China (2) BioMarin Pharmaceutical (1) Pfizer (1) Roche (1) Shanghai Xinzhi BioMed (1) IntraBio (1) Baxalta now part of Shire (1) Biocad (1) Northwell Health (1) Icahn School of Medicine at Mount Sinai (1) Regeneron Pharmaceuticals (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.